Compare neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in age at diagnosis, gender and disease laterality

( views:455, downloads:0 )
Author:
LIU Ran(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University ,Guangzhou 510060 ,China)
LI Jia-qing(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University ,Guangzhou 510060 ,China)
ZENG Jing(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center, Sun Yat-sen University ,Guangzhou 510060 ,China)
()
()
()
()
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
Volume 28, Issue 05, 2012
DOI:
10.3760/cma.j.issn.1005-1015.2012.05.004
Key Word:
Choroid diseases; Macular degeneration; Disease attributes; Age of onset; Sex distributiony

Abstract: Objective To compare neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in age at diagnosis,gender and disease laterality.Methods One hundred fourteen nAMD patients (114 eyes) and 145 PCV patients (186 eyes) diagnosed by fundus fluorescein angiography (FFA) and indocyanine green angiography were enrolled in this retrospective study.The age at diagnosis,gender and disease laterality of all the patients were collected.Independent sample t-test,x2 test and Fisher's exact test were used to compare the age at diagnosis,gender and disease laterality between nAMD and PCV patients.Results The mean age at diagnosis of nAMD group and PCV group were (68.30±9.86),(65.67±9.04) years respectively,the difference was statistically significant (t=-2.168,P=0.031).The patients under 70 years old accounts for 50.88% in nAMD group,which is lower than that in PCV group (63.45%),the difference was statistically significant (x2 =4.138,P=0.042).The male/female ratio of nAMD group and PCV group were 3.56:1 and 2.02∶1 respectively,the difference was statistically significant (x2=3.937,P=0.047).Thirty patients (26.32%) and 41 patients (49.46%) were affected unilaterally in nAMD and PCV group,respectively.The difference of bilateral incidence between two groups was not statistically significant (x2=0.123,P=0.726).There were 69 right eyes (47.92%)and 75 left eyes (52.08%) in nAMD group,92 right eyes (49.46%) and 94 left eyes (50.54%) in PCV group.The difference of disease laterality between two groups was not statistically significant (x2 =0.078,P=0.637).Conclusions PCV patients present at younger age than nAMD.nAMD is more prone to affected males than PCV.Nearly a quarter patients are bilateral in nAMD or PCV,there is no difference in bilateral incidence between these two diseases.

  • [1]Yannuzzi LA,Wong DW,Sforzolini BS,et al.Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.Arch Ophthalmol,1999,117:1503-1510.
  • [2]Khan S,Engelbert M,Imamura Y.Polypoidal choroidal vasculopathy:simultaneous indocyanine green Angiography and eye-tracked spectral domain optical coherence tomography findings.Retina,2012,32:1057-1068.
  • [3]Nakata I,Yamashiro K,Yamada R,et al.Significance of C2/CFB variants in age-related macular degeneration and polypoidal choroidal vasculopathy in a Japanese population.Invest Ophthalmol Vis Sci,2012,53:794-798.
  • [4]Gotoh N,Kuroiwa S,Kikuchi T,et al.Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-relatedmacular degeneration.Am J Ophthalmol,2004,138:567-573.
  • [5]Koizumi H,Yamagishi T,Yamazaki T,et al.Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy.Graefe's Arch Clin Exp Ophthalmol,2011,249:1123-1128.
  • [6]Heier JS,Boyer DS,Ciulla TA,et al.Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration:year 1 results of the FOCUS Study.Arch Ophthalmol,2006,124:1532-1542.
  • [7]Kaiser PK,Brown DM,Zhang K,et al.Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of first-year ANCHOR results.Am J Ophthalmol,2007,144:850-857.
  • [8]Koh A,Lee WK,Chen LJ,et al.Everest study:efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy[J/OL].Retina,2012,32:E1[2012-03-21].http://www.ncbi.nlm.nih.gov/ pubmed/22426346.[published online ahead of print].
  • [9]Honda S,Imai H,YamashiroK,et al.Comparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy:a multicenter study in Hyogo prefecture,Japan.Ophthalmologica,2009,223:333-338.
  • [10]Japanese Study Group of Polypoidal Choroidal Vasculopathy.Criteria for diagnosis of polypoidal choroidal vasculopathy.Nihon Ganka Gakkai Zasshi,2005,109:417-427.
  • [11]Yannuzzi LA,Sorenson J,Spaide RF,et al.Idiopathic polypoidal choroidal vasculopathy (IPCV).Retina,1990,10:1-8.
  • [12]Scassellati-Sforzolini B,Mariotti C,Bryan R,et al.Polypoidal choroidal vasculopathy in Italy.Retina,2001,21:121-125.
  • [13]Liu Y,Wen F,Huang S,et al.Subtype lesions of neovascular age-related macular degeneration in Chinese patients.Graefe's Arch Clin Exp Ophthalmol,2007,245:1441-1445.
  • [14]Maruko I,Iida T,Saito M,et al.Clinical characteristics of exudative age-related macular degeneration in Japanese patients.Am J Ophthalmol,2007,144:15-22.
  • [15]Wen F,Chen C,Wu D,et al.Polypoidal choroidal vasculopathy in elderly Chinese patients.Graefe's Arch Clin Exp Ophthalmol,2004,242:625-629.
  • [16]Kwok AK,Lai TY,Chan CW,et al.Polypoidal choroidal vasculopathy in Chinese patients.Br J Ophthalmol,2002,86:892-897.
  • [17]Sho K,Takahashi K,Yamada H,et al.Polypoidal choroidal vasculopathy:incidence,demographic features,and clinical characteristics.Arch Ophthalmol,2003,121:1392-1396.
  • [18]Ciardella AP,Donsoff IM,Huang SJ,et ah Polypoidal choroidal vasculopathy.Surv Ophthalmol,2004,49:25-37.
  • [19]Byeon SH,Lee SC,Oh HS,et al.Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients.Jpn J Ophthalmol,2008,52:57-62.
  • [20]Klein R,Klein BE,Linton KL.Prevalence of age-related maculopathy:the beaver dam eye study.Ophthalmology,1992,99:933-943.
  • [21]Akaza E,Yuzawa M,Matsumoto Y,et al.Role of photodynamic therapy in polypoidal choroidal vasculopathy.Jpn J Ophthalmol,2007,51:270-277.
  • [22]Cackett P,Yeo I,Cheung CM,et al Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age related macular degeneration in Chinese persons.Ophthalmology,2011,118:846-852.
  • [23]Lafaut BA,Leys AM,Snyers B,et al.Polypoidal choroidal vasculopathy in Caucasians.Graefe's Arch Clin Exp Ophthalmol,2000,238:752-759.
  • [24]Yuzawa M.Epidemiology,risk factors and pathogenesis of age-related macular degeneration.Nihon Ganka Gakkai Zasshi,1997,101:705-706.
  • [25]Oshima Y,Ishibashi T,Murata T,et al.Prevalence of age related maculopathy in a representative Japanese population:the Hisayama study.BrJ Ophthalmol,2001,85:1153-1157.
  • [26]Ciardella AP,Donsoff IM,Yannuzzi LA.Polypoidal choroidal vasculopathy.Ophthalmol Clin North Am,2002,15:537-554.
  • [27]Hou J,Tao Y,Li XX,et al Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients.Graefe's Arch Clin Exp Ophthalmol,2011,249:975-979.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn